MCL-1及其抑制剂在血液恶性肿瘤中的研究进展  

Progress of MCL-1 and its inhibitors in hematologic malignancies

作　　者：滕远 李莉娟[1] 张连生[1] Teng Yuan;Li Lijuan;Zhang Liansheng(Second Clinical Medical College of Lanzhou University,Lanzhou 730000,China)

机构地区：[1]兰州大学第二临床医学院,兰州730000

出　　处：《国际肿瘤学杂志》2024年第2期119-122,共4页Journal of International Oncology

基　　金：国家自然科学基金(8236010019);国家血液系统疾病临床医学研究中心委托课题(2021WWA01);兰州市人才创新创业项目(2020-RC-48);兰州大学第二医院萃英科技创新项目(CY2017-ZD04、CY2019-MS14)。

摘　　要：髓细胞白血病1(MCL-1)是一种抗凋亡蛋白,在促进多发性骨髓瘤、急性髓系白血病和非霍奇金淋巴瘤等的细胞存活中起关键作用。MCL-1在多种血液恶性肿瘤中高表达,是导致血液恶性肿瘤患者预后不良及化疗耐药的重要因素之一,因此,MCL-1是血液恶性肿瘤的重要治疗靶点。几种MCL-1抑制剂已进入临床试验阶段,包括S63845、AZD5991、S64315、AMG-176和AMG-397。用于血液恶性肿瘤的治疗方案中既有MCL-1抑制剂单药治疗,也有与B细胞淋巴瘤2抑制剂或免疫调节药物联合治疗,均表明MCL-1抑制剂可能是血液肿瘤靶向治疗的突破口。Myeloid cell leukemia-1(MCL-1)is an anti-apoptotic protein that plays a key role in promoting cell survival in multiple myeloma,acute myeloid leukemia and non-Hodgkin lymphoma.MCL-1 is highly expressed in a variety of hematological malignancies,which is one of the important factors leading to poor prognosis and chemoresistance in patients with hematological malignancies.Therefore,MCL-1 is an important therapeutic target for hematological malignancies.Several MCL-1 inhibitors have entered clinical trials,including S63845,AZD5991,S64315,AMG-176,and AMG-397.The treatment plans used for hematological malignancies include monotherapy with MCL-1 inhibitors,as well as combination therapy with B cell lymphoma 2 inhibitors or immunomodulatory drugs,all indicating that MCL-1 inhibitors may be a breakthrough point for targeted treatment of hematological malignancies.

关 键 词：血液肿瘤 髓细胞白血病1 抑制剂 

分 类 号：R733[医药卫生—肿瘤]